Subarachnoid Hemorrhage
Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
Subtype terms (1)
More specific conditions that are subtypes of Subarachnoid Hemorrhage in the MeSH hierarchy.
Drugs by status
Approved for this indication (1)
Phase 4 trials (22)
Phase 3 trials (32)
- simvastatin
- edoxaban
- heparin
- sintrom
- vitamin e
- dabigatran
- porcine brain-derived peptide preparation
- norepinephrine
- astragalus membranaceus
- ketamine
- warfarin
- vitamin c
- phenindione
- atorvastatin
- aluminum hydroxide
- magnesium sulfate
- red blood cells
- shuxuening
- alteplase
- dapsone
- thiamine
- dexmedetomidine
- rivaroxaban
- bivalirudin
- apixaban
- tranexamic acid
- lactic acid
- anakinra
- dexamethasone
- zinc
- +2 more
Phase 2 trials (29)
- sodium nitrite
- C1 Esterase Inhibitor (Human)
- dantrolene
- deferoxamine
- dornase alfa
- erythropoetin beta
- galantamine
- fludrocortisone
- gsk2256294
- xenon-129
- baricitinib
- indocyanine green
- deferiprone
- levosimendan
- prolycopene
- bromocriptine
- ropivacaine
- donepezil
- tiopronin
- sildenafil
- oxygen
- morphine
- milrinone
- tirofiban
- epoprostenol
- sulforaphane
- nadroparin
- osu 6162
- nerinetide
Phase 1 trials (11)
Organizations
Organization Involved with Phase 4 Indications (24)
- The Medicines Company
- Ortho Biotech, Inc.
- University of Roma La Sapienza
- Ascension Health
- University of Pittsburgh
- Azienda Ospedaliera San Gerardo di Monza
- Iwate Medical University
- Methodist Healthcare
- Postgraduate Institute of Medical Education and Research
- Tohoku University
- University of Louisville
- University of Milan
- University of South Florida
- Yamaguchi University
- Mayo Clinic
- University of Cincinnati
- University of Debrecen
- Vanderbilt University
- Pennsylvania State University
- University of Sao Paulo
- Ospedale Maggiore San Giovanni Bosco
- Nakamura Memorial Hospital
- Ootemachi Hospital
- Mayfield Clinic & Spine Institute
Organization Involved with Phase 3 Indications (49)
- Actelion
- Fresenius
- Edge Therapeutics Inc
- Unity Health Toronto
- Ain Shams University
- Changhai Hospital
- Johns Hopkins University
- NHS Lothian
- The First People's Hospital of Changzhou
- University of Edinburgh
- University of Lausanne
- University of Manchester
- University of Ottawa
- University of Toronto
- Utrecht University
- Wuhan University
- Chinese University of Hong Kong
- General Committee of Teaching Hospitals and Institutes, Egypt
- Kwong Wah Hospital
- Netherlands Organisation for Scientific Research
- Zhengzhou University
- University of Cambridge
- Zhejiang University
- Shandong University
- University of Amsterdam
- Salford Royal Foundation NHS Trust
- University of Angers
- University of Western Brittany
- University of Strasbourg
- University of Montpellier
- +19 more
Organization Involved with Phase 2 Indications (50)
- Roche
- Evgen Pharma
- Hope Pharmaceuticals
- Prolong Pharmaceuticals
- NoNO Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- American Heart Association
- Barrow Neurological Institute
- University of London
- Harvard University
- Federal University of Rio Grande do Sul
- University of Washington
- Henry Ford Health System
- Indiana University
- Medical University Innsbruck
- Oregon Health and Science University
- Osaka University
- Radboud University
- Thomas Jefferson University
- University of Florida
- University of Groningen
- University of Iowa
- University of Maryland
- University of Michigan
- University of Nebraska
- University of Oslo
- Yale University
- University of Virginia
- University of Zurich
- Assiut University
- +20 more
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (8)